The Chronic Care Policy Alliance released the following statement in response to the Most Favored Nation Executive Order issued by the White House on September 13:
“Yesterday, President Trump issued an executive order to set prices for prescription medications in Medicare Parts B and D based on drug prices in foreign countries. Unfortunately, many of these countries reduce their overall drug prices by also restricting access to innovative treatments and therapies, and it is likely that, by adopting their price controls, the same limits on patient access to prescription medications will be implemented here in the United States. This is a bad deal for Americans with chronic conditions.
“This misguided policy could also disrupt the development of desperately needed new treatments and potential cures. This is especially troubling given the ongoing pandemic, when innovation and research are more important than ever. Therefore, on behalf of the chronic disease community, we urge the Trump administration to abandon this harmful policy and instead implement patient-focused reforms that will bring down costs while preserving access to vital medications.”